Advertise With UsAdvertise on our extensive network of industry websites and newsletters.
Get the PBR newsletterSign up to our free email to get all the latest PBR
news.Apceth has received the second round of funding for the development of stem cell-based cancer therapeutic as part of the m4 initiative of the Munich Biotech Cluster.
Subscribe to our email newsletter
The cancer therapeutic based on patient’s own modified adult mesenchymal stem cells is running under the portfolio name Agenmestencel-T.
In December 2012 apceth has concluded the first round of funding through the Federal Ministry of Education and Research (BMBF) for the development of Agenmestencel-T as part of the Munich Biotech Cluster initiative m4 Personalized Medicine and Targeted Therapies.
Apceth’s total approved budget for the development of Agenmestencel-T came to €4.7m within a period of less than five years between July 2010 and March 2015.